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Introduction
Hyaluronan is a ubiquitous glycosaminoglycan composed of
an unbranched linear chain of repeating D-glucuronic acid and
N-acetyl-D-glucosamine disaccharide units, which commonly
reaches a size of 4 MDa. Unlike other glycosaminoglycans,
hyaluronan is never covalently attached to a protein core or
modified by sulphation yet despite this simplicity of structure,
hyaluronan has a surprisingly wide range of physiological roles
(Laurent and Fraser, 1992) (for reviews, see Hyaluronan Today
at http://www.glycoforum.gr.jp). In general, these can be
divided into two broad but overlapping categories. First,
hyaluronan has a structural role within the extracellular matrix
because of its expanded coil conformation, which in solution
can assume a hydrated sphere morphology. This allows
hyaluronan to create and fill extracellular space thus regulating
cell movement and the transport of extracellular components
(Laurent and Fraser, 1992; Lee and Spicer, 2000; Toole, 2004).
In addition, hyaluronan can associate non-covalently with
proteoglycans such as aggrecan or versican to form large
aggregates that are stabilised by the hyaluronan-binding link
proteins (Day and Prestwich, 2002). Although these properties
of hyaluronan regulate various aspects of cell behaviour, in
particular cell migration, it is increasingly clear that
hyaluronan has a second, more direct role in controlling
cellular responses via its ability to bind to specific hyaluronan
receptors on the cell surface (Ponta et al., 2003; Turley et al.,
2002).
To date, CD44 is the best characterised transmembrane
hyaluronan receptor and because of its wide distribution is
considered to be the major hyaluronan receptor on most cell
types. Work from a large number of laboratories has
established that CD44 can function as an adhesion receptor and
can mediate rolling, attachment and migration of cells on a
hyaluronan substratum. In addition, as has been demonstrated
for all of the other major adhesion receptors, binding of ligand
can result in CD44-mediated transduction of intracellular
signals leading to changes in cell proliferation, survival and
differentiation (Ponta et al., 2003; Thorne et al., 2004; Toole,
2004). More recently, a number of other transmembrane
hyaluronan receptors have been identified (Day and Prestwich,
2002), indicating that cells may use more than one mechanism
to respond to ligand and that when interpreting cellular
responses to hyaluronan it is important to identify the particular
receptor(s) involved.
Much of the interest in hyaluronan has arisen from its
association with pathological processes, particularly cancer
(Toole, 2004). Accumulations of hyaluronan have been
demonstrated in association with many malignant tumours and
there is now extensive data correlating hyaluronan deposition
with enhanced metastatic cell behaviour and poor patient
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The accumulation of the extracellular matrix
glycosaminoglycan hyaluronan by tumours and tumour-
associated stroma promotes cancer cell invasion and
metastasis. Using the Dunn chamber chemotaxis assay, we
demonstrate for the first time that high molecular mass
hyaluronan acts as a soluble chemoattractant promoting
the directional migration of MDA-MB-468 and MDA-MB-
231 breast cancer cells. Moreover, chemotaxis towards
hyaluronan, but not foetal bovine serum, can be abrogated
following treatment of the cells with siRNA
oligonucleotides to downregulate CD44 expression. These
data indicate that CD44 is the principal receptor mediating
this response and that CD44 expression is not a general
requirement for cell migration and gradient sensing, rather
it elicits a ligand-specific response. However, expression of
CD44 alone is not sufficient to drive chemotaxis towards
hyaluronan, as NIH-3T3 fibroblasts were unable to respond
to a hyaluronan gradient even when transfected with high
levels of human CD44. For NIH-3T3 cells to bind
exogenous hyaluronan, it was necessary to both increase
the level of receptor expression and remove a hyaluronan
pericellular matrix. Together, these studies reveal a direct
mechanism for promoting cell invasion into the
hyaluronan-rich matrix and predict that in the complex
multicellular environment in vivo, multiple mechanisms
exist to regulate the ability of a cell to respond to a
chemotactic hyaluronan gradient.
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survival (Anttila et al., 2000; Auvinen et al., 2000; Lipponen et
al., 2001). Hyaluronan is produced by hyaluronan synthases
localised at the cell surface (HAS1, HAS2 and HAS3) and, in
tumours, increased production by the tumour-associated
stromal cells or by the tumour cells themselves is commonly
observed. Experimental evidence that hyaluronan has a role in
tumour progression has come from studies in which hyaluronan
levels have been manipulated. For example, overexpression of
a hyaluronan synthase in prostate and mammary carcinoma cell
lines results in enhanced tumour growth (Liu et al., 2001), loss
of contact inhibition and promotion of cell migration (Itano et
al., 1999). Conversely, transfection of prostate cancer cells with
HAS2 or HAS3 antisense constructs or intravenous
administration of mice bearing human breast cancer xenografts
with hyaluronidase,  results in reduced tumour growth (Shuster
et al., 2002; Simpson et al., 2002). In vitro studies on similarly
manipulated cell lines have indicated that the increased tumour
cell invasion associated with an increased level of hyaluronan
in the matrix results from the hyaluronan clearing a migratory
path by excluding crosslinked fibrous proteins from the matrix
and acting as a scaffold for migrating cells (Toole et al., 2002).
However, there is also increasing evidence that the signalling
functions of hyaluronan are important in these events, both for
promoting tumour cell growth and survival and as a
chemoattractant source for the directional migration of tumour
cells and infiltrating angiogenic endothelial cells. What is less
clear is whether these signalling events are mediated by specific
forms of hyaluronan, in particular by hyaluronan size. As stated
above, hyaluronan is synthesised as large 100-1000 kDa
unbranched chains (high molecular mass hyaluronan) but it can
be degraded in the matrix by hyaluronidases or the action of
reactive oxygen species to give rise to intermediate size
hyaluronan (~10 to ~100 kDa) or small fragments (4-25
disaccharides) (Stern, 2003). Interest in these breakdown
products has come from the demonstration in vitro that cells
respond differently to variously sized hyaluronan preparations
(Noble, 2002; Rooney et al., 1995; Tammi et al., 2002) and in
particular that the angiogenic response to hyaluronan is size
dependent (Lees et al., 1995; West et al., 1985). In addition,
increased levels of small hyaluronan fragments have been
demonstrated in prostate tumours (Lokeshwar et al., 2001), the
saliva of patients with head and neck squamous cell carcinoma
(Franzmann et al., 2003) and the serum of patients with renal
cancer (Kumar et al., 1989). However, in the majority of studies
there has been no systematic attempt to determine whether the
small hyaluronan fragments identified in association with
human tumours play any biological role or that their presence
simply reflects an increased rate of hyaluronan production and
turnover.
In order to gain a better understanding of the role of
hyaluronan in promoting tumour progression we investigated
whether hyaluronan could act as a chemotactic signal for
tumour cells. Further, as the predominant hyaluronan present
associated with human tumours in vivo is of high molecular
mass (Franzmann et al., 2003; Lokeshwar et al., 2001) we
focussed our studies on this hyaluronan species.
Materials and Methods
Cell lines and antibodies
MDA-MB-468 and MDA-MB-231 cells were obtained from ATCC
and cultured in DMEM plus 10% foetal bovine serum (FBS). NIH-
3T3 cells were obtained from C. Marshall (Institute of Cancer
Research, London, UK) and were cultured in DMEM plus 10% donor
calf serum (DCS). Cells were transfected with either pSR vector
alone or pSR vector containing the standard form of human CD44
(pSR-CD44) (Neame and Isacke, 1993) using the Lipofectamine
reagent (Invitrogen) according to the manufacturer’s instructions.
Stable transfectants were selected in 0.6 mg/ml G418 (Invitrogen) and
a population of cells expressing equivalent levels of human CD44
selected by FACS. Monoclonal antibodies used were E1/2.8 specific
for human CD44 (Isacke et al., 1986), IM7.8.1 recognising human and
mouse CD44 (Trowbridge et al., 1982), KM201 specific for mouse
CD44 (Miyake et al., 1990), anti-DAF antibody IA10 (BD
Biosciences) and anti--tubulin (Sigma). Chimaeric constructs in
which either the human CD44 extracellular domain or the Endo180
extracellular domain (Endo180CTLD5-8-Fc) (Wienke et al., 2003)
were fused in-frame with the Fc tail of human IgG1 were expressed
in COS cells, purified on Protein G-Sepharose as previously described
(Wienke et al., 2003) and used at 5 g/ml for flow cytometry. Alexa-
conjugated secondary antibodies were purchased from Molecular
Probes. HRP-conjugated secondary antibodies were purchased from
Jackson ImmunoResearch, phycoerythrin (PE)-conjugated anti-
human Fc was purchased from Sigma. Western blotting,
immunofluorescence staining and confocal microscopy were
performed as previously described (Sullivan et al., 2003).
Hyaluronan and hyaluronidase
Hyaluronan from human umbilical cords with a peak molecular mass
of ~200 kDa (McKee et al., 1996) was purchased from ICN.
Streptococcal hyaluronan with a molecular mass of ~760 kDa was
purchased from Calbiochem. Streptococcal hyaluronan was directly
conjugated to FITC as previously described (de Belder and Wik,
1975) and used for flow cytometry and immunofluorescence at 10
g/ml. Hyaluronidase (type IV-S or from Streptomyces
hyalurolyticus, Sigma) was added to the cells at 30 U/ml in DMEM
with 10% FBS and incubated for 1 hour at 37°C. Cells were then
washed twice with PBS.
siRNA
The following small interfering (siRNA) oligonucleotides were used:
CD44 siRNA oligonucleotides, 5-GUAUGACACAUAUUGCUUC
dT dT-3 and 5-GAAGCAAUAUGUGUCAUAC dT dT-3 (Roscic-
Mrkic et al., 2003); control oligonucleotides, 5-UCUACUCUUC-
CUUCUGCAACCC dT dT-3 and 5-GGGUAGCAGAAGGAGU-
AGA dT dT-3. Annealed siRNA oligonucleotides (0.2 nM) were
transfected into MDA-MB-468 cells seeded onto glass coverslips (30-
50% confluent) with 100 M oligofectamine (Invitrogen) in Opti-
MEM reduced-serum medium (Invitrogen). Cells were incubated at
37°C for 4 hours before the addition of FCS to 10% and cultured for
a further 72 hours before the commencement of further assays.
Chemotaxis assays
Chemotaxis was measured by direct observation and recording of cell
behaviour in stable concentration gradients using Dunn chemotaxis
chambers (Hawksley Technology, Lancing, UK) as described
previously (Allen et al., 1998; Sturge et al., 2002; Zicha and Dunn,
1995). Glass coverslips were coated with either 1% Matrigel (BD
Biosciences) in DMEM (MDA-MB-468 and MDA-MB-231) or 1
g/ml laminin (BD Biosciences, cat. no. 354232) in PBS (NIH-3T3)
for 1 hour at room temperature and then washed twice with DMEM
before cell plating. In all cases, cells were starved in DMEM with
0.25% of the appropriate serum for 12 hours before setting up the
chemotaxis chambers. Gradients of FBS (MDA-MB-468 and MDA-
MB-231) or DCS (NIH-3T3) were formed by placing DMEM
Journal of Cell Science 118 (21)
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containing 10% of the relevant serum in the outside well and 0.25%
in the inside well. Umbilical cord or streptococcal hyaluronan
gradients were formed by placing a 400 g/ml dilution of hyaluronan
in DMEM with 0.25% serum in the outside well and DMEM with
0.25% serum in the inside well. For no gradient control chambers,
DMEM with 0.25% serum was placed in both inside and outside
wells. Fields were selected and filmed with a time-lapse interval of
10 minutes for 8 hours and Kinetic Imaging (Nottingham, UK)
Motion Analysis software used to register cell tracks. Data were then
analysed using a Mathematica (Wolfram Research, Illinois, USA)
notebook written by D. Zicha (Cancer Research UK, London, UK).
In determining the directional responses, only cells migrating to a
certain ‘horizon’ distance were included in the calculation. The
horizon distance was defined as the distance migrated from the
starting position by 90% of cells, a value determined arbitrarily to
enable a highly stringent statistical test (see below). For cells passing
the horizon, x/y coordinates from each movie frame were used to
calculate the mean angle of movement. These angles were then
displayed in a circular histogram where each bar represents the total
number of cells with an angle of migration lying within an 18°
interval. The Rayleigh test for unimodal clustering of directions was
used to determine whether there was a significant chemotactic
response. This statistical test verifies the significance of the mean
direction in a circular histogram. Note, this analysis only provides a
measurement of statistical significance and not a measurement of the
strength of the chemotactic response. A uniform distribution (random
cell motility) of the data was assumed if the P-value for the calculation
was greater than 0.05. A significant chemotactic response is indicated
on the circular histogram by a red arrow showing the mean angle of
migration and green sector indicating the 95% confidence interval.
Isolation of detergent-insoluble raft domains
Biochemical isolation of detergent-insoluble raft domains was
performed essentially as previously described (Thorne et al., 2000)
but with minor modifications. Briefly, cells were grown to 80%
confluence and then further incubated in low-serum medium (0.25%
FBS) for 2-16 hours before addition of 50-100 g/ml hyaluronan for
5-10 minutes at 37°C. Cells were then lysed in 1% Triton X-100 in
MES-buffered saline (pH 6.8) and the sample adjusted to 40% sucrose
(w/v) before fractionation by ultracentrifugation in a discontinuous
5/30/40% sucrose gradient. The detergent-insoluble material was
collected from the 5/30% sucrose interface together with a sample of
soluble lysate from the 40% sucrose layer. The protein concentration
of each sample was determined using the BCA assay (Pierce Chemical
Company) and equivalent protein amounts subjected to
electrophoresis and western blotting.
Results
High molecular mass hyaluronan can mediate cell
chemotaxis
Increased accumulation of hyaluronan around solid tumours is
associated with increased cancer cell invasion and metastasis.
It has been suggested that this, at least in part, reflects the
ability of hyaluronan to promote chemotaxis. Although the
majority of hyaluronan in the extracellular matrix is of high
molecular mass, most studies examining the pro-chemotactic
role of hyaluronan have focussed on small hyaluronan
fragments. To the best of our knowledge, the studies performed
here are the first systematic attempt to determine whether high
molecular mass hyaluronan can promote directional cell
migration. Initially, the breast cancer cell lines, MDA-MB-468
and MDA-MB-231, were tested for their ability to migrate
directionally up a gradient of a known chemoattractant, FBS
or hyaluronan using a Dunn chemotaxis chamber. In this
system, cells are directly viewed and filmed over an 8-hour
period, following which the direction of migration can be
measured by tracking the movement of individual cells. The
advantage of this approach is that cell directionality is
measured independently of cell speed. As expected, both cell
lines migrated in a directional manner towards FBS. In
addition, both cell lines also migrated in a directional manner
when plated in a gradient of high molecular mass (~200 kDa)
umbilical cord hyaluronan (Fig. 1). To determine whether this
was an artefact due to the particular hyaluronan employed, it
was also demonstrated that MDA-MB-468 cells showed
directional migration towards streptococcal hyaluronan (~760
kDa) but only displayed random migration when no gradient
was present.
Hyaluronan-dependent chemotaxis requires expression
of the hyaluronan receptor CD44
Directional migration requires that cells sense a gradient of
chemoattractant and that this in turn leads to their polarization.
Fig. 1. Directional migration of cells in a hyaluronan gradient. The
directional migration of MDA-MB-468 and MDA-MB-231 cells was
assayed in a Dunn chemotaxis chamber. The gradients employed
were 0.25% to 10% FBS, 0 to 400 g/ml umbilical cord hyaluronan,
0 to 400 g/ml streptococcal hyaluronan or no gradient (0.25% FBS
in both chambers). The data are presented as a circular histogram in
which each 18° segment represents the total number of cells with an
average angle of migration falling within that particular interval. The
Rayleigh test for unimodal clustering is used to verify directional
migration. If cells show statistically significant directional migration,
the mean migration angle is displayed as a red arrow and the 95%
confidence interval as a green sector. The number of cells analysed
for each treatment is given.
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To date, the best characterised hyaluronan transmembrane
receptor is CD44 and flow cytometric staining demonstrated
that both MDA-MB-468 and MDA-MB-231 cells express
uniformly high levels of CD44 (Fig. 2A). Immunofluorescence
staining also revealed a typical CD44 distribution with the
receptor strongly expressed at the plasma membrane and little
or no intracellular staining (Fig. 2B). Using hyaluronan
conjugated to FITC, it was demonstrated that MDA-MB-468
and MDA-MB-231 cells could bind hyaluronan as assayed
both by flow cytometry (Fig. 2A) and fluorescence microscopy
(Fig. 2B) although, as discussed later, despite similar levels of
CD44 expression MDA-MB-231 cells bind less hyaluronan
than MDA-MB-468 cells. A number of transmembrane
receptors, other than CD44, which contain the hyaluronan-
binding Link module have been reported (Day and Prestwich,
2002). These include Lyve-1, which is expressed
predominantly on lymphatic endothelium (Jackson, 2003;
Prevo et al., 2001), members of the stabilin family, which are
reported to function as hyaluronan internalisation receptors on
hepatic sinusoidal endothelial cells (Harris et al., 2004; Politz
et al., 2002), potentially Toll-like receptor 4 (TLR4) (Taylor et
al., 2004; Termeer et al., 2002) as well as a cell-associated
hyaluronan binding protein, RHAMM (Turley et al., 2002). To
address the possibility that a non-CD44 hyaluronan receptor
might be responsible for sensing the hyaluronan gradient, we
used small interfering double stranded RNA (siRNA) to
downregulate CD44 expression. By flow cytometric analysis,
siRNA directed towards CD44 resulted in a substantial
decrease in CD44 expression whereas no effect was seen in
mock-transfected cells or cells transfected with a control
siRNA (Fig. 3A). Importantly, this downregulation of CD44
expression also resulted in a substantial reduction in FITC-
hyaluronan binding as monitored both by flow cytometry (Fig.
3A) and fluorescence microscopy (Fig. 3B). Treatment of cells
with CD44 siRNA, but not with control siRNA, also resulted
in loss of the ability of the cells to migrate in a directional
manner towards a hyaluronan source. This was not a global
impairment of chemotaxis however as cells treated with CD44
siRNA retained their ability to migrate directionally up a
gradient of FBS (Fig. 3C).
Hyaluronan binding does not alter the distribution of
CD44 in detergent-insoluble lipid raft domains
Recently, it has been demonstrated that lipid rafts can play an
important role in providing the spatial cell polarity required for
chemotaxis (Gomez-Mouton et al., 2004; Manes et al., 2003).
CD44 is known to partition into detergent-insoluble raft
domains in a cell type-specific manner (Neame et al.,
1995; Perschl et al., 1995a) and suggestively, in
immortalised mammary epithelial cell lines, this
association was demonstrated to stabilise the interaction
of CD44 with the actin cytoskeleton (Foger et al., 2001;
Oliferenko et al., 1999). We therefore sought to determine
if CD44 was partitioned into the lipid rafts of the breast
cancer cell lines studied here and if so, whether the
proportion of CD44 in the rafts was altered following
hyaluronan binding. MDA-MB-468 cells were lysed in
Triton X-100 buffer and fractionated on sucrose density
gradients to prepare detergent-insoluble raft and
detergent-soluble fractions as described in the Materials
and Methods. Western blotting of equal amounts of
protein from each fraction revealed that in MDA-MB-468
(Fig. 4) and MDA-MB-231 cells (data not shown) CD44
was enriched in the raft fraction. To validate the isolation
procedures, western blotting of replicate samples revealed
that decay accelerating factor (DAF) was found
exclusively in the detergent-insoluble raft fraction as
would be expected for a GPI-anchored protein, whereas
-tubulin was located exclusively in the detergent-soluble
fraction. Addition of umbilical cord hyaluronan (Fig. 4)
or streptococcal hyaluronan (data not shown) under any
of the conditions tested did not increase the association of
CD44 with lipid rafts indicating that, at least in these
breast cancer cell lines, further raft recruitment of CD44
is not required for cell chemotaxis.
The chemotactic response to hyaluronan is
dependent on cell type 
The data presented here strongly suggest that the
migration of breast cancer epithelial cells towards
hyaluronan is dependent on CD44 expression (Fig. 3). To
further investigate whether the chemotactic response
towards hyaluronan is a common feature of CD44-
Journal of Cell Science 118 (21)
Fig. 2. MDA-MB-468 and MDA-MB-231 cells express CD44 and exhibit
constitutive hyaluronan binding. (A) Cells cultured overnight were
detached and stained for flow cytometry. For CD44 expression, cells were
incubated either with anti-CD44 monoclonal antibody E1/2 followed by
Alexa555 anti-mouse Ig (red graph) or with secondary antibody alone
(black graph). For hyaluronan binding, cells were either incubated with
FITC-conjugated hyaluronan (FITC-HA, green graph) or medium alone
(black graph). (B) MDA-MB-468 cells cultured overnight on glass
coverslips were incubated with FITC-hyaluronan for 1 hour at 37°C
(green) and then fixed, permeabilised and stained with the anti-CD44
monoclonal antibody E1/2 followed by Alexa555 anti-mouse Ig (red).
Nuclei were visualised with TO-PRO-3 (blue). Bar, 50 m.
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5123Cell chemotaxis towards hyaluronan
expressing cells, we evaluated NIH-3T3 fibroblasts in the Dunn
chemotaxis chamber assay. Western blot analysis using
monoclonal IM7 antibody, which recognises both human and
mouse CD44, and monoclonal antibody KM201, which is
specific for mouse CD44, demonstrated that like MDA-MB-
468 and MDA-MB-231 cells, NIH-3T3 cells predominantly
express CD44 of a molecular mass consistent with the standard
CD44 isoform, CD44s (Fig. 5).
Analysis of the NIH-3T3 cells in the hyaluronan chemotaxis
assay unexpectedly revealed that although these cells were able
to migrate towards a gradient of DCS, only random migration
was observed when these cells were plated in a gradient of
Fig. 4. Effect of hyaluronan binding on the partitioning of
CD44 into detergent-insoluble lipid rafts. MDA-MB-468 cells
were incubated without or with 100 g/ml umbilical cord
hyaluronan before preparation of detergent-insoluble lipid rafts
(RAFT) and soluble fractions (SOL) as described in the
Materials and Methods. Protein equivalents (5 g) were
separated by electrophoresis and western blotted for CD44
(monoclonal antibody E1/2), DAF and -tubulin. Positions of
molecular size markers are indicated in kDa.
Fig. 3. CD44 expression is required for sensing a hyaluronan gradient.
(A,B) MDA-MB-468 cells were left untreated, mock transfected,
transfected with control siRNA oligonucleotides or transfected with CD44
siRNA oligonucleotides. 72 hours later cells were detached from dishes
and CD44 expression and hyaluronan binding assessed by flow cytometry
or fluorescence microscopy as described in Fig. 2. In A, black lines
represent binding of second antibody alone (CD44) or medium alone
(FITC-HA) to untreated cells. (C) MDA-MB-468 cells transfected with
CD44 or control siRNA oligonucleotides were assayed for their ability
to migrate directionally in a gradient of FBS or umbilical cord
hyaluronan as described in Fig. 1. Bar, 50 m.
Fig. 5. Generation of a murine fibroblast line overexpressing human
CD44s. MDA-MB-468 cells, MDA-MB-231 cells and NIH-3T3 cells
transfected with pSR vector alone and NIH-3T3 cells expressing
human CD44s were lysed and subjected to western blotting with
anti-human CD44 monoclonal antibody E1/2, monoclonal antibody
IM7, which recognises both human and murine CD44, or anti-murine
CD44 monoclonal antibody KM201. Positions of molecular size
markers are indicated in kDa.
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hyaluronan (Fig. 6A). Further analysis of these cells by flow
cytometry demonstrated that despite CD44 being readily
detected at the cell surface, there was essentially no binding of
FITC-hyaluronan (Fig. 6B). This lack of hyaluronan binding
provides an explanation as to why these cells do not migrate
in a hyaluronan gradient, but raises the issue as to why a CD44-
expressing cell line does not bind ligand. It is well recognised
that a threshold of CD44 expression is required before
hyaluronan binding is observed (Perschl et al., 1995b; Tzircotis
et al., 2004; Uff et al., 1995) and it was notable by western
blotting that the level of CD44 expression in NIH-3T3 cells
was lower than that observed in the MDA-MB-468 and MDA-
MB-231 breast cancer lines (Fig. 5). To address this, NIH-3T3
cells were transfected with a human CD44s construct and by
FACS sorting with the human CD44 specific monoclonal
antibody E1/2, a population of cells which stably expressed
human CD44 at a level equivalent to that found in the breast
epithelial lines was selected (Fig. 5 and Fig. 6B). Western blot
analysis of these human CD44s-transfected NIH-3T3 cells
provides further evidence that both the NIH-3T3 cells and the
breast cancer cell lines predominantly express CD44s (Fig. 5).
Despite this increased expression, no directional migration of
the CD44s-transfected NIH-3T3 cells in a hyaluronan gradient
was observed (Fig. 6A) and surprisingly, binding of FITC-
hyaluronan remained at background levels (Fig. 6B). This
inability of the exogenously expressed human CD44s to bind
ligand is not due to a defect in the human CD44s cDNA, as
transfection of CD44-negative human melanoma cells and
mouse T lymphoma cells with the same construct has
previously been demonstrated to result in CD44s expression
and efficient hyaluronan binding (Peck and Isacke, 1996; Uff
et al., 1995). Consequently, it is valid to conclude that CD44
is modified in a cell type-specific manner to modulate ligand
binding and hence cellular responses to hyaluronan.
To date, the best characterised mechanism for regulating
hyaluronan binding to CD44s is variable extracellular domain
glycosylation (Lesley et al., 1997) and it is evident that the
relative role of N- and O-linked glycosylation and modification
by chondroitin sulphate in this process is dependent on cell
type (Bartolazzi et al., 1996; Bennett et al., 1995; Lesley et al.,
1995; Skelton et al., 1998). Although there is a strong
likelihood that CD44 glycosylation plays a role in modulating
hyaluronan binding to NIH-3T3 cells, we wished to investigate
whether additional mechanisms preventing binding were
involved. Fibroblasts, which are known to synthesise
hyaluronan, may have assembled a hyaluronan-containing
matrix on their surface, which prevents binding of exogenously
added ligand. Vector alone and human CD44s expressing NIH-
3T3 cells pretreated with or without hyaluronidase were
assessed for their ability to bind a CD44-Fc chimaeric protein
which serves as a hyaluronan binding probe (Peach et al., 1993)
(Fig. 7A). As a control, cells were incubated with an Fc
chimaera containing the extracellular domain of an unrelated
receptor, Endo180 (Wienke et al., 2003). In both vector alone
and CD44s transfected cells, an equivalent level of CD44-Fc
binding was observed which was significantly reduced in
hyaluronidase-treated cells, indicating that these cells are
surrounded by a hyaluronan-containing pericellular matrix.
Additional control experiments demonstrated increased CD44-
Fc binding to MDA-MB-468 cells following preincubation
with exogenously added hyaluronan and that hyaluronidase
treatment of these cells did not alter CD44 expression levels
(data not shown). Although both vector alone and CD44s-
expressing NIH-3T3 cells have a hyaluronan coat, only the
CD44s-expressing cells show an increase in FITC-hyaluronan
binding following hyaluronidase treatment. In addition, the
flow cytometric analysis indicates that this increase is variable
within the population. These data were confirmed by confocal
microscopy (Fig. 7B) where it is shown that following
hyaluronidase treatment, only cells expressing human CD44s
were able to bind exogenously added FITC-hyaluronan. Note
that NIH-3T3 cells sit flatter on the substratum than MDA-MB-
468 cells (see Fig. 2) and therefore the plasma membrane
expression of CD44 and the binding of FITC-hyaluronan to the
NIH-3T3 cell surface is observed in a single low power
confocal section. However, clearly not all transfected cells
exhibited efficient binding, indicating that multiple
mechanisms exist to regulate hyaluronan binding to these cells.
Finally, it was important to determine whether this blocking of
exogenous hyaluronan binding by a hyaluronan pericellular
Journal of Cell Science 118 (21)
Fig. 6. NIH-3T3 fibroblasts do not migrate towards hyaluronan.
(A) NIH-3T3 fibroblasts transfected with vector alone or human
CD44s were assayed for their ability to migrate towards DCS (0.25-
10.00% gradient) or umbilical cord hyaluronan (0-400 g/ml
gradient) as described in Fig. 1. (B) Cells were subjected to flow
cytometry to monitor expression of murine CD44 using monoclonal
antibody KM201 (blue), expression of human CD44 using
monoclonal antibody E1/2 (red) and FITC-HA binding (green) as
described in Fig. 2.
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matrix is a feature of other cell types. MDA-MB-468 cells,
which constitutively bind high levels of hyaluronan (Fig. 2),
showed essentially no increase in hyaluronan binding
following hyaluronidase treatment (Fig. 7C). MDA-MB-231
cells which constitutively bind comparatively lower levels of
hyaluronan exhibited a twofold increase in binding following
hyaluronidase treatment although this binding did not reach the
levels shown by the MDA-MB-468 cells (Fig. 7C).
Discussion
Directional migration of breast cancer cells towards
hyaluronan is dependent on CD44
In this report, we establish that high molecular mass
hyaluronan can act as a chemoattractant in a rigorous
directional migration assay. In particular, we have
demonstrated that human breast cancer cells will migrate
directionally when placed in a gradient of either umbilical cord
or streptococcal hyaluronan. Moreover, using siRNA
oligonucleotides directed against CD44 we have demonstrated
that this migration is dependent on CD44. This latter
experiment also established two other important issues. First,
the impairment of chemotaxis in cells treated with CD44
siRNA oligonucleotides demonstrates that the directional
migration observed does not result from a pro-chemotactic
contaminant in the hyaluronan preparations used. This is
important given previous reports that responses ascribed to
hyaluronan have been due to impurities in the preparations
(Filion and Phillips, 2001). It should also be noted that
although NIH-3T3 cells display a chemotactic response to
serum they do not migrate directionally in a hyaluronan
gradient, further supporting the assertion that the responses
observed in the breast cancer cell lines are specific for
hyaluronan. Second, as CD44 siRNA treatment did not impair
chemotaxis towards a serum gradient (which contains a
cocktail of chemotactic agents) it can be concluded that CD44
expression is not a general requirement for cell migration and
gradient sensing, rather it elicits a ligand-specific response.
Like all the major classes of adhesion receptor, CD44 lacks
intrinsic kinase activity, raising the question as to the
mechanism by which it modulates cellular responses to a
soluble ligand. Previous studies from our and other laboratories
have shown that the cytoplasmic domain of CD44 can associate
with members of the ERM (ezrin, radixin, moesin) family of
actin binding linker proteins (Legg and Isacke, 1998; Morrison
et al., 2001; Yonemura et al., 1998) and that this interaction is
an important component of the chemotactic response (Legg et
al., 2002). One mechanism that has been suggested to regulate
the association of CD44 with the actin cytoskeleton is its
Fig. 7. Hyaluronan binding of human CD44s expressing NIH-3T3
cells after hyaluronidase treatment. (A) NIH-3T3 cells transfected
with vector alone or human CD44s were detached from culture
dishes, resuspended in DMEM plus 10% DCS and treated with S.
hyalurolyticus hyaluronidase. After washing twice in PBS, cells were
incubated either with FITC-hyaluronan (FITC-HA, green) or CD44-
Fc (red). As controls, cells were also incubated with Endo180-Fc
(grey) or medium alone (black). Fc chimaeras were detected with
PE-anti-human Fc. (B) NIH-3T3 cells transfected with vector alone
or human CD44s were cultured on coverslips overnight and then
treated with type IV-S hyaluronidase. After washing, cells were
stained with FITC-hyaluronan (green) and anti-human CD44
monoclonal antibody E1/2 (red) as described in Fig. 2. Nuclei were
visualised with TO-PRO-3 (blue). To illustrate the variation in FITC-
hyaluronan binding following hyaluronidase treatment, two separate
fields of view are shown (lower two rows). (C) MDA-MB-468 and
MDA-MB-231 cells were analysed by flow cytometry for FITC-HA
binding following treatment with either medium alone (green) or
treatment with S. hyalurolyticus hyaluronidase (dotted green). Black
lines represent binding of secondary antibody alone. Bar, 100 m.
Jo
ur
na
l o
f C
el
l S
ci
en
ce
5126
recruitment into lipid rafts (Foger et al., 2001; Oliferenko et
al., 1999) and it has been reported that treatment of MDA-MB-
231 cells with hyaluronan increased the proportion of
detergent-insoluble CD44 in the cell (Bourguignon et al.,
2004). To investigate whether such recruitment was occurring
in our cells, we solubilised cells in cold detergent and
fractionated the lysate by sucrose density centrifugation. Under
these conditions, a substantial proportion of CD44 was
detected in detergent-insoluble lipid rafts but this proportion
did not change in cells previously incubated with hyaluronan.
Although these data indicate that further recruitment of CD44
into rafts is not required for the chemotactic response, it does
not preclude the hypothesis that a raft-associated population of
CD44 is required for directional migration. In leukocytes, there
is increasing evidence that the redistribution of specific
membrane microdomains during cell migration is necessary for
the establishment of cell polarity. This results from membrane
rafts acting as a platform to assemble signalling complexes in
a polarised fashion (Gomez-Mouton et al., 2004; Manes et al.,
2003). Certainly, it will be important to assess whether
hyaluronan does indeed cause a redistribution of raft-
associated CD44 in polarised cells.
Cell type specificity of hyaluronan-dependent
chemotaxis
Although we demonstrate here that CD44 expression is
required for a cell to migrate towards a hyaluronan gradient, it
is well accepted that not all CD44-positive cells are competent
to bind hyaluronan (Lesley et al., 1993). To date, three major
mechanisms have been reported which regulate the ability of
CD44 to bind its ligand: the level of receptor expression
(Perschl et al., 1995b; Uff et al., 1995), expression of particular
alternatively spliced CD44 isoforms (Stamenkovic et al., 1991)
and receptor glycosylation (Lesley et al., 1997). We show here
that murine NIH-3T3 fibroblasts do not bind exogenously
added hyaluronan and do not migrate directionally in a
hyaluronan gradient. Moreover, as hyaluronan binding was
also not observed in human CD44s-transfected NIH-3T3 cells,
it can be concluded that the inability of these fibroblasts to bind
ligand is not due to these cells expressing a non-binding or
alternatively spliced CD44 isoform. What our data indicate is
that binding of exogenously added hyaluronan to human
CD44s-transfected NIH-3T3 cells is impaired by the presence
of a hyaluronan containing pericellular matrix but that removal
of the matrix does not restore efficient hyaluronan binding to
all CD44s-expressing cells. This strongly suggests that binding
of hyaluronan to these cells is regulated by additional
mechanisms such as variable receptor glycosylation.
It was also observed in these experiments that NIH-3T3 cells
transfected with vector alone had a hyaluronan coat, as
evidenced by their ability to bind CD44-Fc, but were unable to
bind FITC-hyaluronan following hyaluronidase treatment.
This raises the issue as to how such a coat might persist if the
CD44, or any other hyaluronan receptor, expressed on these
cells cannot bind ligand. The most likely explanation for this
apparent contradiction is that in these cells the hyaluronan
matrix is not anchored to the cell surface by CD44. Hyaluronan
is produced by hyaluronan synthases localized in the plasma
membrane and it has been demonstrated that hyaluronan can
be tethered to the cell surface by retention in the synthase,
resulting in assembly of a CD44-independent pericellular
matrix (Heldin and Pertoft, 1993; Spicer and McDonald,
1998). Finally, it is important to note that the presence of cell
surface-associated hyaluronan does not necessarily result in a
complete block of exogenous hyaluronan binding. In MDA-
MB-231 cells, the presence of a pericellular matrix only results
in a partial impairment of hyaluronan binding ability and
untreated cells are able to migrate directionally up a
hyaluronan gradient. It is therefore likely that mechanisms
regulating hyaluronan binding, such as receptor modification
and receptor blocking, are not mutually exclusive but may act
in concert.
Hyaluronan-CD44 interactions in pathological states
The studies undertaken here have two important implications
when considering the role of hyaluronan in tumour cell
invasion. First, we demonstrate that high molecular mass
hyaluronan can mediate tumour cell chemotaxis. This suggests
that in addition to the well-established role for hyaluronan in
promoting cell migration, there is a direct mechanism for
promoting the infiltration of cells into the surrounding matrix
particularly where large accumulations of hyaluronan occur in
the tumour-associated stroma (Anttila et al., 2000; Auvinen et
al., 2000). Second, in the breast cancer cell lines that showed
a positive response to the gradient of high molecular mass
hyaluronan, CD44 was demonstrated to be the sole hyaluronan
receptor responsible for mediating these effects. However, as
illustrated by the studies on NIH-3T3 fibroblasts, expression of
CD44 per se is not sufficient to promote chemotaxis, rather the
receptor must be competent to bind ligand. Here we
demonstrate two mechanisms for modulating ligand binding in
cells: levels of receptor expression and the presence of a
hyaluronan pericellular matrix. Thus, we predict that multiple
mechanisms will exist in an in vivo multicellular environment
that regulate the ability of the cell to respond to a chemotactic
gradient of hyaluronan.
The data presented initially may seem at variance with
current trends to assign different cellular responses to
hyaluronan of distinct sizes. In general, high molecular mass
hyaluronan has been associated with structural roles (as a
space-filling molecule, a component of the pericellular matrix
and a scaffold for migrating cells) whereas it has been
suggested that hyaluronan fragments are more biologically
active with respect to stimulating signal transduction in cells.
This stems, at least in part, from early demonstrations that
hyaluronan oligosaccharides promote angiogenesis whereas
high molecular mass hyaluronan does not (Rooney et al., 1995)
and more recent reports that smaller hyaluronan fragments are
more potent than higher molecular mass material in promoting
gene transcription and random cell migration when added to
cells in vitro (Sugahara et al., 2003; Turley et al., 2002).
However, none of these studies rigorously assessed the role of
hyaluronan in promoting cell chemotaxis and certainly high
molecular mass hyaluronan can activate signalling events in a
wide variety of cells. We propose that both specific effects of
hyaluronan fragments and high molecular mass hyaluronan can
act together in the complex multicellular environment in vivo
as in pathological conditions, both hyaluronan production and
the presence of hyaluronan fragments/oligosaccharides is
increased. Given that hyaluronan oligosaccharides can displace
Journal of Cell Science 118 (21)
Jo
ur
na
l o
f C
el
l S
ci
en
ce
5127Cell chemotaxis towards hyaluronan
hyaluronan bound to the cell surface (Tammi et al., 1998), it is
tempting to speculate that this may provide a mechanism by
which cells non-responsive to hyaluronan switch to a
responsive mode, activating signalling pathways leading to the
chemotactic migration towards high molecular mass ligand.
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